Tenalisib manufacturers
- Tenalisib
-
- $38.00
-
2026-07-27
- CAS:1639417-53-0
- Purity: 99.71%
- Supply Ability: 10g
- Tenalisib
-
- $38.00
-
2026-07-27
- CAS:1639417-53-0
- Purity: 99.71%
- Supply Ability: 10g
|
| | Tenalisib Basic information |
| Product Name: | Tenalisib | | Synonyms: | RP6530;Tenalisib;Tenalisib (RP6530);RP6530, Tenalisib;Tenalisib (Synonyms: RP6530);RP-6530; RP 6530; RP6530;4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-;(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one | | CAS: | 1639417-53-0 | | MF: | C23H18FN5O2 | | MW: | 415.42 | | EINECS: | | | Product Categories: | | | Mol File: | 1639417-53-0.mol |  |
| | Tenalisib Chemical Properties |
| Boiling point | 706.1±60.0 °C(Predicted) | | density | 1.434±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 100 mg/mL (240.72 mM) | | form | Solid | | pka | 10.06±0.10(Predicted) | | color | White to off-white |
| | Tenalisib Usage And Synthesis |
| Uses | Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and PI3Kγ inhibitor with IC50 values of 25 and 33 nM, respectively. | | in vivo | Tenalisib has been well tolerated in subjects with heavily pre-treated relapsed/refractory hematologic malignancies. Reported toxicities are manageable with no DLTs. Single agent activity is evident in difficult-to-treat subjects at ≥ 200 mg BID[2]. | | IC 50 | PI3Kδ: 25 nM (IC50); PI3Kγ: 33 nM (IC50) | | References | [1] Vakkalanka S, et al. RP6530, a dual PI3K δ/γ inhibitor, potentiates ruxolitinib activity in the JAK2-V617F mutant erythroleukemia cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2704. doi:10.1158/1538-7445.AM2015-2704
[2] Carmelo C, et al. A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood 2015 126:1495; |
| | Tenalisib Preparation Products And Raw materials |
|